Finally, given the increased interest in the use of GH as a therapeutic agent to “treat” obesity (30) and the intense activity in the clinical development of JAK2 inhibitors for the treatment of cancer and inflammatory diseases, this work has significant translational implications (31, 32). Here, JAK2 is linked to obesity due to melanocortin 4 receptor deficiency.